Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 110

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 110
---
iture Agreement and the transactions contemplated by the Divestiture Agreement, including the Divestiture, and (3) recommending that our stockholders vote in favor of the approval of the Divestiture Agreement, Aadi’s board of directors was aware of and considered these interests to the extent that they existed or were otherwise known at the time, among other matters. These interests are more fully described in this section. Retention Bonus Letters Aadi has entered into Retention Bonus Letters with each of Dr. Lennon and Messrs. Giacobello and Ball, pursuant to which each executive is eligible to be paid a Retention Bonus subject to continued employment with the Company through the earlier of (i) March 31, 2025, or (ii) the date of a Change in Control (as defined in the applicable Retention Bonus Letter), provided that an executive will remain eligible to receive the Retention Bonus if his employment is terminated by the Company other than for Cause, death or disability, or if he resigns for Good Reason (each such term as defined in the applicable Retention Bonus Letter), subject to execution of a separation agreement and release of claims in favor of the Company. Although it is expected that the Divestiture will notconstitute a Change in Control for purposes of the Retention Bonus Letters, in an abundance of caution, Aadi is treating the Retention Bonus Letter as an interest of the executive officers in the Divestiture for purposes of this proxy statement. The amount of such Retention Bonus is $390,000 for Dr. Lennon, $220,000 for Mr. Giacobello and $210,000 for Mr. Ball. Additionally, it is expected that Dr. Lennon, Mr. Giacobello and Mr. Ball will continue to serve as executive officers of Aadi following the Divestiture and that all members of Aadi’s board of directors will continue to serve thereon following the Divestiture, and that such officers and directors will continue to receive cash and other compensation (including benefits) for such services under applicable plans and arrangements which may be funded with proceeds from the Divestiture. Accounting Treatment The Divestiture will be accounted for as a “sale” by Aadi, as that term is used under generally accepted accounting principles, for accounting and financial reporting purposes. - 71 -

Material U.S. Federal Income Tax Consequences of the Divestiture

The following discussionis asummary of the material anticipated U.S. federal income tax consequences of the Divestiture. This